Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Immune Thrombocytopenia (ITP) Companies

Immune thrombocytopenia (ITP) is a disorder characterized by a low platelet count, leading to an increased risk of bleeding. Treatment for ITP may involve medications, such as immunosuppressants or thrombopoietin receptor agonists, as well as other therapeutic approaches.

Latest Immune Thrombocytopenia Companies Update

December 2022: Argenx SE, a multinational immunology corporation dedicated to enhancing the quality of life for individuals afflicted with severe autoimmune disorders, disclosed results from its Phase 3 ADVANCE trial. The ADVANCE study represents the initial phase of two registrational trials that aim to assess the safety, effectiveness, and tolerability of VYVGART® (efgartigimod alfa-fcab) in adult patients diagnosed with primary ITP. ADVANCE represents the second Phase 3 clinical trial in which VYVGART exhibited a substantial clinical advantage, thereby reinforcing the investigators' conviction regarding the extensive potential of this asset across various IgG-mediated autoimmune diseases with high need. Chronic ITP patients who received VYVGART demonstrated a sustained platelet response (17/78; 21.8%) in comparison to those who received a placebo (2/40; 5%), according to the study. Between weeks 19 and 24 of treatment, sustained platelet response was characterized as platelet counts of 50x109/L or higher at a minimum of four of the last six scheduled visits.

January 2023: Bruker Corporation announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions for high-content microscopy and bioimaging, in January 2023. This acquisition provides networking technology, secure storage, and high-performance on-premise processing that enhance Bruker's advanced fluorescence microscopy imaging products, including light-sheet and super-resolution microscopy products, which produce substantial amounts of data. The development of the ACQUIFER HIVE system was motivated by the need to manage the exponential growth of data generated by life science research. By integrating Bruker's light-sheet microscopy instrumentation with their fluorescence microscopy platforms, they are now capable of providing a comprehensive solution for the management of large data and advanced imaging.

List of Immune Thrombocytopenia Key companies in the market

CSL Limited

Amgen Inc.

F.Hoffmann-La Roche Ltd.

Kyowa Hakko Kirin Co., Ltd

Rigel Pharmaceuticals, Inc.

Shionogi Inc.

Dova Pharmaceuticals

Novartis AG

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Shire

Ligand Pharmaceuticals, Inc.

Immune Thrombocytopenia (ITP) Market Highlights:

Immune Thrombocytopenia (ITP) Market Size

Immune Thrombocytopenia (ITP) Market Trends

Immune Thrombocytopenia (ITP) Market Analysis

Immune Thrombocytopenia (ITP) Market Share

Immune Thrombocytopenia (ITP) Market Highlights:

Immune Thrombocytopenia (ITP) Market Trends

Immune Thrombocytopenia (ITP) Market Analysis

Immune Thrombocytopenia (ITP) Market Share

Immune Thrombocytopenia (ITP) Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.